TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8141126

Group type: EXPERIMENTAL
Intervention: ABO-identical platelet transfusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABO-unmatched platelet transfusions
Number of subjects: 0
Study: 3138681

Group type: EXPERIMENTAL
Intervention: misoprostol 400 micrograms twice daily for 28 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: propranolol 80 mg twice daily for four weeks with misoprostol 400 micrograms twice daily during the second and third weeks
Number of subjects: 12
Study: 31831193

Group type: EXPERIMENTAL
Intervention: No-touch saphenous vein (NT SV) graft
Number of subjects: 108

Group type: COMPARATOR
Intervention: Radial artery (RA) graft
Number of subjects: 108

Group type: COMPARATOR
Intervention: Left internal thoracic artery (LITA)
Number of subjects: 108
Study: 31274266

Group type: EXPERIMENTAL
Intervention: Novel ultrasound-guided bracket-assisted technique for axillary vein catheter placement
Number of subjects: 35
Study: 29848400

Group type: EXPERIMENTAL
Intervention: REACH intervention
Number of subjects: 32000

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 32000
Study: 28372549

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (1.02 g over 2 doses)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Iron sucrose (1.0 g over 10 doses)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Ferumoxytol and iron sucrose
Number of subjects: 296
Study: 24656704

Group type: EXPERIMENTAL
Intervention: Heat patch applied on the lower abdomen for 2 menstrual cycles
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Analgesic medication (single dose)
Number of subjects: 193

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 193
Study: 21957983

Group type: EXPERIMENTAL
Intervention: Narrative communication
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Didactic communication
Number of subjects: 311

Group type: COMPARATOR
Intervention: No message
Number of subjects: 311
Study: 19489872

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 208
Study: 17961229

Group type: EXPERIMENTAL
Intervention: Synthetic folate intake of 151-410 microg/d (2nd quartile)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Plasma folate concentrations at 16 weeks postpartum
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: RBC folate concentrations at 16 weeks postpartum
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Overall blood folate concentrations
Number of subjects: 108
Study: 16240620

Group type: EXPERIMENTAL
Intervention: Silver-releasing hydroalginate dressing (Silvercel)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Pure calcium alginate dressing (Algosteril)
Number of subjects: 99
Study: 12181401

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg daily
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 600 mg daily
Number of subjects: 147
Study: 9542794

Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 8031206

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/d, increased to 40 mg/d and 80 mg/d based on response)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Niacin (1.5 g/d, increased to 3 g/d and 4.5 g/d based on response)
Number of subjects: 136
Study: 2919769

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: No H2-antagonist (Control)
Number of subjects: 30
Study: 31091372

Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg or 110 mg twice daily)
Number of subjects: 5390

Group type: COMPARATOR
Intervention: Aspirin (100 mg once daily)
Number of subjects: 5390

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 5390

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5390
Study: 29175902

Group type: EXPERIMENTAL
Intervention: 150 mg oral aspirin daily for up to 24 weeks
Number of subjects: 251

Group type: COMPARATOR
Intervention: Matching placebo for up to 24 weeks
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 150 mg oral aspirin daily
Number of subjects: 251

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 251
Study: 25499679

Group type: EXPERIMENTAL
Intervention: Pneumatic unloader bracing with extension assist
Number of subjects: 52
Study: 23492458

Group type: EXPERIMENTAL
Intervention: Right-side stellate ganglion block (SGB) using 8 mL 0.75% ropivacaine for 4 times
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline injection (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Right-side stellate ganglion block (SGB)
Number of subjects: 30
Study: 21211691

Group type: EXPERIMENTAL
Intervention: CAP + O(3) exposure
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CAP + O(3) exposure with low-frequency to high-frequency ratio as covariate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CAP + O(3) exposure with high-frequency component as covariate
Number of subjects: 25
Study: 17852073

Group type: EXPERIMENTAL
Intervention: Plasma beta-carotene
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Urinary F2-IsoP
Number of subjects: 60
Study: 16855454

Group type: EXPERIMENTAL
Intervention: Modafinil during open-label treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuation of Modafinil during double-blind treatment phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12603352

Group type: EXPERIMENTAL
Intervention: Hyaluronate‐based gel (HAbg) injected into the thoracic cavity (n = 27 patients)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal saline injected into the thoracic cavity (Control group, n = 25 patients)
Number of subjects: 52
Study: 10837282

Group type: EXPERIMENTAL
Intervention: 5.1 g psyllium twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cellulose placebo
Number of subjects: 0
Study: 9100159

Group type: EXPERIMENTAL
Intervention: Pulmonary hypertensive group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 1609906

Group type: EXPERIMENTAL
Intervention: ARTA public service announcement (appearing six times)
Number of subjects: 907

Group type: COMPARATOR
Intervention: No AIDS public service announcements
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Both groups (with and without ARTA PSA)
Number of subjects: 907
Study: 4029247

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31005929

Group type: EXPERIMENTAL
Intervention: Gut microbiome transfer (28 capsules of frozen microbial suspension)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (28 capsules of saline)
Number of subjects: 80
Study: 29174323

Group type: COMPARATOR
Intervention: 2+1 schedule (PCV13 at 2, 4, and 12 months)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 1+1 schedule (PCV13 at 3 and 12 months)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 1+1 schedule
Number of subjects: 213

Group type: COMPARATOR
Intervention: 2+1 schedule
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Both schedules
Number of subjects: 213
Study: 27422590

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg with telmisartan/amlodipine 40/5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Telmisartan/amlodipine 40/5 mg with rosuvastatin 20 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Telmisartan/amlodipine 40/5 mg
Number of subjects: 48
Study: 25370913

Group type: EXPERIMENTAL
Intervention: Sourdough wholegrain rye bread (WGR)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: White wheat bread enriched with bioprocessed rye bran (BRB+WW)
Number of subjects: 21

Group type: COMPARATOR
Intervention: White wheat bread (WW)
Number of subjects: 21
Study: 22992309

Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 282

Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Needle acupuncture
Number of subjects: 282

Group type: COMPARATOR
Intervention: Natural history group (no acupuncture treatment)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: All treatment groups (Laser, Sham laser, Needle)
Number of subjects: 282
Study: 20384520

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived cells (BMCs)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: CD34(+) cell therapy
Number of subjects: 980
Study: 18555814

Group type: EXPERIMENTAL
Intervention: Observed start (initiation of contraception at the 1-week follow-up visit)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Sunday start (initiation of contraception at the first Sunday following the follow-up visit)
Number of subjects: 261
Study: 16273791

Group type: EXPERIMENTAL
Intervention: TNF blocker therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tuberculin skin testing using PPD
Number of subjects: 0
Study: 12484493

Group type: EXPERIMENTAL
Intervention: Zona thinning (ZT) using a laser diode with 1.48 microm wavelength, 1-2 irradiations of 10 ms applied to four positions on the zona pellucida, thinning 60-90% of the ZP
Number of subjects: 100

Group type: COMPARATOR
Intervention: No zona thinning (Control group)
Number of subjects: 100
Study: 10320530

Group type: EXPERIMENTAL
Intervention: Banked human milk (BBM, n = 87)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Preterm formula (PTF, n = 96)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Term formula (TF, n = 36)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Low-nutrient diet (BBM/TF)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Term children (n = 95)
Number of subjects: 244
Study: 8738880

Group type: EXPERIMENTAL
Intervention: Oxytocin (0.5 IU, intravenous infusion within 2.5 min via a forearm catheter)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2009998

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 1 mg/kg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sulprostone 500 micrograms
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MTX (1 mg/kg) systemic injection on days 3, 5, and 7 after local injection
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sulprostone (500 micrograms) systemic injection on the 1st 2 postlocal injection days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MTX and sulprostone
Number of subjects: 21
Study: 7049099

Group type: EXPERIMENTAL
Intervention: Hypothermic perfusion (cold crystalloid solution)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hypothermic potassium cardioplegia (cold crystalloid solution with 25 mEq/L potassium chloride)
Number of subjects: 50
Study: 30707787

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (activity modification and night-only wrist splints)
Number of subjects: 30
Study: 26759261

Group type: EXPERIMENTAL
Intervention: HP meal (31.9% energy from protein)
Number of subjects: 24

Group type: COMPARATOR
Intervention: HMF meal (35.2% fat and 20.7% monounsaturated fat)
Number of subjects: 24
Study: 27109624

Group type: EXPERIMENTAL
Intervention: GSK1521498 (10 mg OD for 5 days)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX; 25 mg OD for 2 days, then 50 mg OD for 3 days)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: GSK1521498 and Naltrexone
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 56
Study: 24896137

Group type: EXPERIMENTAL
Intervention: Pazopanib 10 mg/mL eye drops, instilled 4 times daily for 12 weeks (Study 2)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Pazopanib 10 mg/mL eye drops, instilled 4 times daily for 2 weeks (Study 1)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo, instilled 4 times daily for 2 weeks (Study 1)
Number of subjects: 55
Study: 21897328

Group type: EXPERIMENTAL
Intervention: Basic fibroblast growth factor (b‐FGF) group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 19212971

Group type: EXPERIMENTAL
Intervention: Drug treatment for low panic-high worry and high panic-high worry sub-groups
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Drug treatment for low panic-low worry subjects
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Drug treatment for high worry subjects
Number of subjects: 170
Study: 17202007

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.75%
Number of subjects: 203

Group type: COMPARATOR
Intervention: Lidocaine 4%
Number of subjects: 203
Study: 15041616

Group type: EXPERIMENTAL
Intervention: SUF group (7.5 microg of sufentanil)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: BSE group (1.5 microg of sufentanil)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: EPD group (7.5 microg of sufentanil)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: CSE groups (BSE and SUF)
Number of subjects: 300
Study: 11174088

Group type: EXPERIMENTAL
Intervention: Moisturiser containing both urea and sodium chloride
Number of subjects: 22

Group type: COMPARATOR
Intervention: Moisturiser containing urea alone
Number of subjects: 22
Study: 9237315

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression (ASD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Open subacromial decompression (OSD)
Number of subjects: 32
Study: 7584264

Group type: EXPERIMENTAL
Intervention: Inhibitory selective attention processes in working memory using a modified Sternberg‐type 'short‐term memory scanning' task.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitory selective attention processes in working memory using a 'negative priming' task.
Number of subjects: 0
Study: 3687783

Group type: EXPERIMENTAL
Intervention: Milrinone (50 micrograms/kg bolus then 0.5 microgram/kg/min)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dobutamine (2.5 to 15 micrograms/kg/min)
Number of subjects: 14
Study: 31923099

Group type: EXPERIMENTAL
Intervention: Keto acid (KA) supplement (0.1 g/kg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (dietary protein intake of 0.9 g/kg/day)
Number of subjects: 29
Study: 29449290

Group type: EXPERIMENTAL
Intervention: ReTrain intervention (including an introductory one-to-one session, ten twice-weekly group classes, a closing one-to-one session, and three drop-in sessions over 3 months)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group received an exercise after stroke advice booklet
Number of subjects: 45
Study: 27134202

Group type: EXPERIMENTAL
Intervention: Metabolic surgery
Number of subjects: 57

Group type: COMPARATOR
Intervention: Medical weight management (MWM)
Number of subjects: 57
Study: 24346625

Group type: EXPERIMENTAL
Intervention: Immediate acupuncture in the first 3 months
Number of subjects: 632

Group type: COMPARATOR
Intervention: Delayed acupuncture in the subsequent 3 months
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Further acupuncture treatment during the follow-up period
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Acupuncture responder at 6 months
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Higher school education
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Not wanting to use medications
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Using additional therapies
Number of subjects: 632
Study: 22288578

Group type: EXPERIMENTAL
Intervention: Walking program conducted once a week for 90 minutes for 3 months
Number of subjects: 150
Study: 20579837

Group type: EXPERIMENTAL
Intervention: Expectancy-enhancing handout and CD
Number of subjects: 53

Group type: COMPARATOR
Intervention: Expectancy-neutral informational handout and CD
Number of subjects: 53
Study: 17286341

Group type: EXPERIMENTAL
Intervention: gender-specific feedback
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: gender-neutral feedback
Number of subjects: 185

Group type: COMPARATOR
Intervention: assessment-only control
Number of subjects: 185
Study: 15644016

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy for dependent smokers
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 210
Study: 12145026

Group type: EXPERIMENTAL
Intervention: Clodronate (1500 mg, intravenously every 3 months for 1 year)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 20
Study: 10103334

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (3 mg/kg/d of elemental zinc as zinc sulfate)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 87
Study: 7757353

Group type: EXPERIMENTAL
Intervention: Regular motor activity of the gastrointestinal tract
Number of subjects: 38
Study: 2083042

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/2% Gantrez copolymer/0.243% sodium fluoride dentifrice
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control dentifrice (same as experimental but without triclosan/copolymer)
Number of subjects: 81
Study: 385025

Group type: EXPERIMENTAL
Intervention: 6 mg piretanide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 9 mg piretanide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1 mg bumetanide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All treatments (6 mg piretanide, 9 mg piretanide, 1 mg bumetanide)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 6 mg piretanide and 9 mg piretanide
Number of subjects: 9
Study: 31014177

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 28044985

Group type: EXPERIMENTAL
Intervention: Drape on patient's arm (Group 2)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Pelvic drape (Group 3)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Combined arm and pelvic drapes (Group 4)
Number of subjects: 452

Group type: COMPARATOR
Intervention: No drapes (Group 1)
Number of subjects: 452
Study: 26149841

Group type: EXPERIMENTAL
Intervention: pGM169/GL67A gene-liposome complex
Number of subjects: 140

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 140
Study: 23827100

Group type: EXPERIMENTAL
Intervention: Prednisolone (PSL, 1.5 mg/kg for 2-4 weeks and subsequently stepwise reduction)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Dexamethasone (HDD, 40 mg/day, d1-4)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Rituximab plus HDD (rituximab 100 mg on days 7, 14, 21, 28 and HDD)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Rituximab plus HDD (R+HDD)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Prednisolone (PSL)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Dexamethasone (HDD)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 138
Study: 21963360

Group type: COMPARATOR
Intervention: Normal night's sleep
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sleep restriction to 5h
Number of subjects: 39
Study: 19768922

Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 1780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1780
Study: 15691867

Group type: EXPERIMENTAL
Intervention: l-NAME (180 µg.kg(‐1).h(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 8
Study: 12162933

Group type: EXPERIMENTAL
Intervention: Inhibitors of cholesterol absorption, acyl coenzyme A‐cholesterol acyltransferase, microsomal triglyceride transfer protein, cholesteryl ester transfer protein, liver X receptor agonists
Number of subjects: 0
Study: 10764243

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (more than 550 cigarette-years of exposure)
Number of subjects: 5488

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (more than 300 cigarette-years of exposure)
Number of subjects: 5488

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (all smokers combined)
Number of subjects: 5488

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (time since last use)
Number of subjects: 5488
Study: 7726492

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg every 12 h for five doses)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Erythromycin (250 mg every 6 h for nine doses)
Number of subjects: 32
Study: 2406324

Group type: EXPERIMENTAL
Intervention: RIT protocol without preventive measures (290 patients)
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: RIT protocol with pretreatment (160 patients)
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: RIT protocol with pretreatment and preventive measures (479 patients)
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Step protocol with pretreatment and preventive measures (223 patients)
Number of subjects: 1152
Study: 7262184

Group type: EXPERIMENTAL
Intervention: Clonidine (1 and 5 micrograms/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Drug-free conditions
Number of subjects: 6
Study: 31150072

Group type: EXPERIMENTAL
Intervention: Violent video game with guns
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Violent video game with swords
Number of subjects: 220

Group type: COMPARATOR
Intervention: Nonviolent video game
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Violent video games (general)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Self-reported exposure to violent media
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Trait aggression
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Firearm safety training course
Number of subjects: 220
Study: 28283676

Group type: EXPERIMENTAL
Intervention: Urine HCMV‐DNA tests (n=197)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Blood HCMV‐DNA tests (n=46)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Serum CMV‐specific IgM testing
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Serum CMV‐specific IgG testing
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Simultaneous blood and urine HCMV‐DNA tests (n=10)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Urine HCMV‐DNA tests in parturients (n=25)
Number of subjects: 243
Study: 26576124

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ethanol ablation (EA)
Number of subjects: 50